
Global Direct Oral Anticoagulants (DOACs) Market Analysis and Forecast 2025-2031
Description
Summary
According to APO Research, The global Direct Oral Anticoagulants (DOACs) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Direct Oral Anticoagulants (DOACs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Direct Oral Anticoagulants (DOACs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Direct Oral Anticoagulants (DOACs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Direct Oral Anticoagulants (DOACs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Direct Oral Anticoagulants (DOACs) include Accord Healthcare, Apotex, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Janssen Pharmaceuticals, Teva Pharmaceutical and Viatris, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Direct Oral Anticoagulants (DOACs), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Direct Oral Anticoagulants (DOACs), also provides the sales of main regions and countries. Of the upcoming market potential for Direct Oral Anticoagulants (DOACs), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Direct Oral Anticoagulants (DOACs) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Direct Oral Anticoagulants (DOACs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Direct Oral Anticoagulants (DOACs) sales, projected growth trends, production technology, application and end-user industry.
Direct Oral Anticoagulants (DOACs) Segment by Company
Accord Healthcare
Apotex
Boehringer Ingelheim
Bristol Myers Squibb
Daiichi Sankyo
GlaxoSmithKline
Janssen Pharmaceuticals
Teva Pharmaceutical
Viatris
Bayer
Pfizer
Mylan
Sandoz
Direct Oral Anticoagulants (DOACs) Segment by Type
Oral Factor Xa Inhibitors
Direct Thrombin Inhibitors (DTIs)
Direct Oral Anticoagulants (DOACs) Segment by Application
Pulmonary Embolism
Deep Vein Thrombosis
Atrial Fibrillation
Other
Direct Oral Anticoagulants (DOACs) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Direct Oral Anticoagulants (DOACs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Direct Oral Anticoagulants (DOACs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Direct Oral Anticoagulants (DOACs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Direct Oral Anticoagulants (DOACs) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Direct Oral Anticoagulants (DOACs) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Direct Oral Anticoagulants (DOACs) sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Direct Oral Anticoagulants (DOACs) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Direct Oral Anticoagulants (DOACs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Direct Oral Anticoagulants (DOACs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Direct Oral Anticoagulants (DOACs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Direct Oral Anticoagulants (DOACs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Direct Oral Anticoagulants (DOACs) include Accord Healthcare, Apotex, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Janssen Pharmaceuticals, Teva Pharmaceutical and Viatris, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Direct Oral Anticoagulants (DOACs), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Direct Oral Anticoagulants (DOACs), also provides the sales of main regions and countries. Of the upcoming market potential for Direct Oral Anticoagulants (DOACs), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Direct Oral Anticoagulants (DOACs) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Direct Oral Anticoagulants (DOACs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Direct Oral Anticoagulants (DOACs) sales, projected growth trends, production technology, application and end-user industry.
Direct Oral Anticoagulants (DOACs) Segment by Company
Accord Healthcare
Apotex
Boehringer Ingelheim
Bristol Myers Squibb
Daiichi Sankyo
GlaxoSmithKline
Janssen Pharmaceuticals
Teva Pharmaceutical
Viatris
Bayer
Pfizer
Mylan
Sandoz
Direct Oral Anticoagulants (DOACs) Segment by Type
Oral Factor Xa Inhibitors
Direct Thrombin Inhibitors (DTIs)
Direct Oral Anticoagulants (DOACs) Segment by Application
Pulmonary Embolism
Deep Vein Thrombosis
Atrial Fibrillation
Other
Direct Oral Anticoagulants (DOACs) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Direct Oral Anticoagulants (DOACs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Direct Oral Anticoagulants (DOACs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Direct Oral Anticoagulants (DOACs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Direct Oral Anticoagulants (DOACs) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Direct Oral Anticoagulants (DOACs) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Direct Oral Anticoagulants (DOACs) sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
195 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Direct Oral Anticoagulants (DOACs) Market by Type
- 1.2.1 Global Direct Oral Anticoagulants (DOACs) Market Size by Type, 2020 VS 2024 VS 2031
- 1.2.2 Oral Factor Xa Inhibitors
- 1.2.3 Direct Thrombin Inhibitors (DTIs)
- 1.3 Direct Oral Anticoagulants (DOACs) Market by Application
- 1.3.1 Global Direct Oral Anticoagulants (DOACs) Market Size by Application, 2020 VS 2024 VS 2031
- 1.3.2 Pulmonary Embolism
- 1.3.3 Deep Vein Thrombosis
- 1.3.4 Atrial Fibrillation
- 1.3.5 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Direct Oral Anticoagulants (DOACs) Market Dynamics
- 2.1 Direct Oral Anticoagulants (DOACs) Industry Trends
- 2.2 Direct Oral Anticoagulants (DOACs) Industry Drivers
- 2.3 Direct Oral Anticoagulants (DOACs) Industry Opportunities and Challenges
- 2.4 Direct Oral Anticoagulants (DOACs) Industry Restraints
- 3 Global Market Growth Prospects
- 3.1 Global Direct Oral Anticoagulants (DOACs) Revenue Estimates and Forecasts (2020-2031)
- 3.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Region
- 3.2.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Region: 2020 VS 2024 VS 2031
- 3.2.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Region (2020-2025)
- 3.2.3 Global Direct Oral Anticoagulants (DOACs) Revenue by Region (2026-2031)
- 3.2.4 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region (2020-2031)
- 3.3 Global Direct Oral Anticoagulants (DOACs) Sales Estimates and Forecasts 2020-2031
- 3.4 Global Direct Oral Anticoagulants (DOACs) Sales by Region
- 3.4.1 Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2020 VS 2024 VS 2031
- 3.4.2 Global Direct Oral Anticoagulants (DOACs) Sales by Region (2020-2025)
- 3.4.3 Global Direct Oral Anticoagulants (DOACs) Sales by Region (2026-2031)
- 3.4.4 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Region (2020-2031)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
- 4 Market Competitive Landscape by Manufacturers
- 4.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Manufacturers
- 4.1.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Manufacturers (2020-2025)
- 4.1.2 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Manufacturers (2020-2025)
- 4.1.3 Global Direct Oral Anticoagulants (DOACs) Manufacturers Revenue Share Top 10 and Top 5 in 2024
- 4.2 Global Direct Oral Anticoagulants (DOACs) Sales by Manufacturers
- 4.2.1 Global Direct Oral Anticoagulants (DOACs) Sales by Manufacturers (2020-2025)
- 4.2.2 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Manufacturers (2020-2025)
- 4.2.3 Global Direct Oral Anticoagulants (DOACs) Manufacturers Sales Share Top 10 and Top 5 in 2024
- 4.3 Global Direct Oral Anticoagulants (DOACs) Sales Price by Manufacturers (2020-2025)
- 4.4 Global Direct Oral Anticoagulants (DOACs) Key Manufacturers Ranking, 2023 VS 2024 VS 2025
- 4.5 Global Direct Oral Anticoagulants (DOACs) Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global Direct Oral Anticoagulants (DOACs) Manufacturers, Product Type & Application
- 4.7 Global Direct Oral Anticoagulants (DOACs) Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global Direct Oral Anticoagulants (DOACs) Market CR5 and HHI
- 4.8.2 2024 Direct Oral Anticoagulants (DOACs) Tier 1, Tier 2, and Tier 3
- 5 Direct Oral Anticoagulants (DOACs) Market by Type
- 5.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Type
- 5.1.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2020 VS 2024 VS 2031)
- 5.1.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2020-2031) & (US$ Million)
- 5.1.3 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2020-2031)
- 5.2 Global Direct Oral Anticoagulants (DOACs) Sales by Type
- 5.2.1 Global Direct Oral Anticoagulants (DOACs) Sales by Type (2020 VS 2024 VS 2031)
- 5.2.2 Global Direct Oral Anticoagulants (DOACs) Sales by Type (2020-2031) & (K Units)
- 5.2.3 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2020-2031)
- 5.3 Global Direct Oral Anticoagulants (DOACs) Price by Type
- 6 Direct Oral Anticoagulants (DOACs) Market by Application
- 6.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Application
- 6.1.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2020 VS 2024 VS 2031)
- 6.1.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2020-2031) & (US$ Million)
- 6.1.3 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2020-2031)
- 6.2 Global Direct Oral Anticoagulants (DOACs) Sales by Application
- 6.2.1 Global Direct Oral Anticoagulants (DOACs) Sales by Application (2020 VS 2024 VS 2031)
- 6.2.2 Global Direct Oral Anticoagulants (DOACs) Sales by Application (2020-2031) & (K Units)
- 6.2.3 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2020-2031)
- 6.3 Global Direct Oral Anticoagulants (DOACs) Price by Application
- 7 Company Profiles
- 7.1 Accord Healthcare
- 7.1.1 Accord Healthcare Comapny Information
- 7.1.2 Accord Healthcare Business Overview
- 7.1.3 Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.1.4 Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolio
- 7.1.5 Accord Healthcare Recent Developments
- 7.2 Apotex
- 7.2.1 Apotex Comapny Information
- 7.2.2 Apotex Business Overview
- 7.2.3 Apotex Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.2.4 Apotex Direct Oral Anticoagulants (DOACs) Product Portfolio
- 7.2.5 Apotex Recent Developments
- 7.3 Boehringer Ingelheim
- 7.3.1 Boehringer Ingelheim Comapny Information
- 7.3.2 Boehringer Ingelheim Business Overview
- 7.3.3 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.3.4 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolio
- 7.3.5 Boehringer Ingelheim Recent Developments
- 7.4 Bristol Myers Squibb
- 7.4.1 Bristol Myers Squibb Comapny Information
- 7.4.2 Bristol Myers Squibb Business Overview
- 7.4.3 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.4.4 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolio
- 7.4.5 Bristol Myers Squibb Recent Developments
- 7.5 Daiichi Sankyo
- 7.5.1 Daiichi Sankyo Comapny Information
- 7.5.2 Daiichi Sankyo Business Overview
- 7.5.3 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.5.4 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolio
- 7.5.5 Daiichi Sankyo Recent Developments
- 7.6 GlaxoSmithKline
- 7.6.1 GlaxoSmithKline Comapny Information
- 7.6.2 GlaxoSmithKline Business Overview
- 7.6.3 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.6.4 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolio
- 7.6.5 GlaxoSmithKline Recent Developments
- 7.7 Janssen Pharmaceuticals
- 7.7.1 Janssen Pharmaceuticals Comapny Information
- 7.7.2 Janssen Pharmaceuticals Business Overview
- 7.7.3 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.7.4 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolio
- 7.7.5 Janssen Pharmaceuticals Recent Developments
- 7.8 Teva Pharmaceutical
- 7.8.1 Teva Pharmaceutical Comapny Information
- 7.8.2 Teva Pharmaceutical Business Overview
- 7.8.3 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.8.4 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolio
- 7.8.5 Teva Pharmaceutical Recent Developments
- 7.9 Viatris
- 7.9.1 Viatris Comapny Information
- 7.9.2 Viatris Business Overview
- 7.9.3 Viatris Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.9.4 Viatris Direct Oral Anticoagulants (DOACs) Product Portfolio
- 7.9.5 Viatris Recent Developments
- 7.10 Bayer
- 7.10.1 Bayer Comapny Information
- 7.10.2 Bayer Business Overview
- 7.10.3 Bayer Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.10.4 Bayer Direct Oral Anticoagulants (DOACs) Product Portfolio
- 7.10.5 Bayer Recent Developments
- 7.11 Pfizer
- 7.11.1 Pfizer Comapny Information
- 7.11.2 Pfizer Business Overview
- 7.11.3 Pfizer Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.11.4 Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolio
- 7.11.5 Pfizer Recent Developments
- 7.12 Mylan
- 7.12.1 Mylan Comapny Information
- 7.12.2 Mylan Business Overview
- 7.12.3 Mylan Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.12.4 Mylan Direct Oral Anticoagulants (DOACs) Product Portfolio
- 7.12.5 Mylan Recent Developments
- 7.13 Sandoz
- 7.13.1 Sandoz Comapny Information
- 7.13.2 Sandoz Business Overview
- 7.13.3 Sandoz Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.13.4 Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolio
- 7.13.5 Sandoz Recent Developments
- 8 North America
- 8.1 North America Direct Oral Anticoagulants (DOACs) Market Size by Type
- 8.1.1 North America Direct Oral Anticoagulants (DOACs) Revenue by Type (2020-2031)
- 8.1.2 North America Direct Oral Anticoagulants (DOACs) Sales by Type (2020-2031)
- 8.1.3 North America Direct Oral Anticoagulants (DOACs) Price by Type (2020-2031)
- 8.2 North America Direct Oral Anticoagulants (DOACs) Market Size by Application
- 8.2.1 North America Direct Oral Anticoagulants (DOACs) Revenue by Application (2020-2031)
- 8.2.2 North America Direct Oral Anticoagulants (DOACs) Sales by Application (2020-2031)
- 8.2.3 North America Direct Oral Anticoagulants (DOACs) Price by Application (2020-2031)
- 8.3 North America Direct Oral Anticoagulants (DOACs) Market Size by Country
- 8.3.1 North America Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 8.3.2 North America Direct Oral Anticoagulants (DOACs) Sales by Country (2020 VS 2024 VS 2031)
- 8.3.3 North America Direct Oral Anticoagulants (DOACs) Price by Country (2020-2031)
- 8.3.4 United States
- 8.3.5 Canada
- 8.3.6 Mexico
- 9 Europe
- 9.1 Europe Direct Oral Anticoagulants (DOACs) Market Size by Type
- 9.1.1 Europe Direct Oral Anticoagulants (DOACs) Revenue by Type (2020-2031)
- 9.1.2 Europe Direct Oral Anticoagulants (DOACs) Sales by Type (2020-2031)
- 9.1.3 Europe Direct Oral Anticoagulants (DOACs) Price by Type (2020-2031)
- 9.2 Europe Direct Oral Anticoagulants (DOACs) Market Size by Application
- 9.2.1 Europe Direct Oral Anticoagulants (DOACs) Revenue by Application (2020-2031)
- 9.2.2 Europe Direct Oral Anticoagulants (DOACs) Sales by Application (2020-2031)
- 9.2.3 Europe Direct Oral Anticoagulants (DOACs) Price by Application (2020-2031)
- 9.3 Europe Direct Oral Anticoagulants (DOACs) Market Size by Country
- 9.3.1 Europe Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 9.3.2 Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2020 VS 2024 VS 2031)
- 9.3.3 Europe Direct Oral Anticoagulants (DOACs) Price by Country (2020-2031)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Russia
- 9.3.9 Spain
- 9.3.10 Netherlands
- 10 China
- 10.1 China Direct Oral Anticoagulants (DOACs) Market Size by Type
- 10.1.1 China Direct Oral Anticoagulants (DOACs) Revenue by Type (2020-2031)
- 10.1.2 China Direct Oral Anticoagulants (DOACs) Sales by Type (2020-2031)
- 10.1.3 China Direct Oral Anticoagulants (DOACs) Price by Type (2020-2031)
- 10.2 China Direct Oral Anticoagulants (DOACs) Market Size by Application
- 10.2.1 China Direct Oral Anticoagulants (DOACs) Revenue by Application (2020-2031)
- 10.2.2 China Direct Oral Anticoagulants (DOACs) Sales by Application (2020-2031)
- 10.2.3 China Direct Oral Anticoagulants (DOACs) Price by Application (2020-2031)
- 11 Asia (Excluding China)
- 11.1 Asia Direct Oral Anticoagulants (DOACs) Market Size by Type
- 11.1.1 Asia Direct Oral Anticoagulants (DOACs) Revenue by Type (2020-2031)
- 11.1.2 Asia Direct Oral Anticoagulants (DOACs) Sales by Type (2020-2031)
- 11.1.3 Asia Direct Oral Anticoagulants (DOACs) Price by Type (2020-2031)
- 11.2 Asia Direct Oral Anticoagulants (DOACs) Market Size by Application
- 11.2.1 Asia Direct Oral Anticoagulants (DOACs) Revenue by Application (2020-2031)
- 11.2.2 Asia Direct Oral Anticoagulants (DOACs) Sales by Application (2020-2031)
- 11.2.3 Asia Direct Oral Anticoagulants (DOACs) Price by Application (2020-2031)
- 11.3 Asia Direct Oral Anticoagulants (DOACs) Market Size by Country
- 11.3.1 Asia Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 11.3.2 Asia Direct Oral Anticoagulants (DOACs) Sales by Country (2020 VS 2024 VS 2031)
- 11.3.3 Asia Direct Oral Anticoagulants (DOACs) Price by Country (2020-2031)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
- 12 South America, Middle East and Africa
- 12.1 SAMEA Direct Oral Anticoagulants (DOACs) Market Size by Type
- 12.1.1 SAMEA Direct Oral Anticoagulants (DOACs) Revenue by Type (2020-2031)
- 12.1.2 SAMEA Direct Oral Anticoagulants (DOACs) Sales by Type (2020-2031)
- 12.1.3 SAMEA Direct Oral Anticoagulants (DOACs) Price by Type (2020-2031)
- 12.2 SAMEA Direct Oral Anticoagulants (DOACs) Market Size by Application
- 12.2.1 SAMEA Direct Oral Anticoagulants (DOACs) Revenue by Application (2020-2031)
- 12.2.2 SAMEA Direct Oral Anticoagulants (DOACs) Sales by Application (2020-2031)
- 12.2.3 SAMEA Direct Oral Anticoagulants (DOACs) Price by Application (2020-2031)
- 12.3 SAMEA Direct Oral Anticoagulants (DOACs) Market Size by Country
- 12.3.1 SAMEA Direct Oral Anticoagulants (DOACs) Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 12.3.2 SAMEA Direct Oral Anticoagulants (DOACs) Sales by Country (2020 VS 2024 VS 2031)
- 12.3.3 SAMEA Direct Oral Anticoagulants (DOACs) Price by Country (2020-2031)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
- 13 Value Chain and Sales Channels Analysis
- 13.1 Direct Oral Anticoagulants (DOACs) Value Chain Analysis
- 13.1.1 Direct Oral Anticoagulants (DOACs) Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 Direct Oral Anticoagulants (DOACs) Production Mode & Process
- 13.2 Direct Oral Anticoagulants (DOACs) Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 Direct Oral Anticoagulants (DOACs) Distributors
- 13.2.3 Direct Oral Anticoagulants (DOACs) Customers
- 14 Concluding Insights
- 15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.